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Abstract 1 
Recent studies suggest that exposure to some plasticizers, such as Bisphenol A (BPA), play 2 
a role in endocrine/metabolic dispruption and can affect lipid accumulation in adipocytes.  3 
Here, we investigated the adipogenic activity and nuclear receptor interactions of four 4 
plasticizers approved for the manufacturing of food-contact materials (FCMs) and currently 5 
considered safer alternatives.  Differentiating 3T3-L1 mouse preadipocytes were exposed 6 
to scalar concentrations (0.01-25 µM) of DiNP (Di-iso-nonyl-phthalate), DiDP (Di-iso-decyl-7 
phthalate), DEGDB (Diethylene glycol dibenzoate), or TMCP (Tri-m-cresyl phosphate). 8 
Rosiglitazone, a well-known pro-adipogenic peroxisome proliferator activated receptor 9 
gamma (PPARγ) agonist, and the plasticizer BPA were included as reference compounds. 10 
All concentrations of plasticizers were able to enhance lipid accumulation, with TMCP being 11 
the most effective one. Accordingly, when comparing in silico the ligand binding efficiencies 12 
to the nuclear receptors PPARγ and retinoid-X-receptor-alpha (RXRα), TMPC displayed the 13 
highest affinity to both receptors. Differently from BPA, the four plasticizers were most 14 
effective in enhancing lipid accumulation when added in the mid-late phase of differentiation, 15 
thus suggesting the involvement of different intracellular signalling pathways. In line with 16 
this, TMCP, DiDP, DiNP and DEGDB were able to activate PPARγ in transient transfection 17 
assays, while previous studies demonstrated that BPA acts mainly through other nuclear 18 
receptors. qRT-PCR studies showed that all plasticizers were able to increase the 19 
expression of CCAAT/enhancer binding protein β (Cebpβ) in the early steps of adipogenesis, 20 
and the adipogenesis master gene Pparγ2 in the middle phase, with very similar efficacy to 21 
that of Rosiglitazone. In addition, TMCP was able to modulate the expression of both Fatty 22 
Acid Binding Protein 4/Adipocyte Protein 2 (Fabp4/Ap2) and Lipoprotein Lipase (Lpl) 23 
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transcripts in the late phase of adipogenesis. DEGDB increased the expression of Lpl only, 1 
while the phthalate DiDP did not change the expression of either late-phase marker genes 2 
Fabp4 and Lpl. Taken together, our results suggest that exposure to low, environmentally 3 
relevant doses of the plasticizers DiNP, DiDP DEGDB and TMCP increase lipid 4 
accumulation in 3T3-L1 adipocytes, an effect likely mediated through activation of PPARγ 5 
and interference at different levels with the transcriptional cascade driving adipogenesis. 6 
 7 
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1. Introduction 1 
Obesity is the fastest growing health problem in Europe and worldwide. In the European 2 
Union, overweight affects between 36% and 67.5% of adults, while obesity affect between 3 
10% and 28% of adults (last update 2014) [1].  In addition to genetic factors, life style factors 4 
such as excessive caloric intake, high fat diets, and low physical activity contribute to 5 
obesity. However, there is also increasing evidence that environmental pollutants including 6 
endocrine-disrupting chemicals (EDCs) may contribute to the development of obesity and 7 
metabolic disorders.  A subset of EDCs have been named ”obesogens” or “metabolic 8 
disruptors” [2–5], because of their ability to promote adiposity by altering fat cell 9 
development and increasing energy storage of fat tissue, and because of their implication in 10 
metabolic syndrome and obesity [6]. 11 
The EU regulation (1907/2006 and subsequent updates) regarding the Registration, 12 
Evaluation, Authorisation and Restriction of Chemicals (REACH) has identified so far 181 13 
substances  of very high concern (SVHC) for the environment and human health (last update 14 
January 2018). Several SVHC are plasticizers, a class of diverse additives used in plastics 15 
production, that are poorly bound or not bound to the polymers. These features facilitate 16 
their migration from food-contact materials (FCMs) and several household plastic items, thus 17 
coming in contact with humans through food consumption, skin absorption and inhalation 18 
[7]. FCMs, including plastic packaging, are not generally perceived to be a chemical health 19 
threat when compared to pesticides, veterinary drugs or heavy metals arising from 20 
agricultural practices or environmental contamination. However, within the last decade it has 21 
been increasingly reported that certain FCMs can act like EDCs [8]; a good example are 22 
plastic additives used in food containers like Bisphenol A (BPA), a substance recently 23 
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included in the SVHC list  and whose impact on the endocrine system has been increasingly 1 
reported [2,3]. 2 
The EFSA (European Food Safety Authority) regulation 10/2011 has provided a list of 3 
plasticizers permitted in EU for FCMs manufacturing, which has become a useful source of 4 
alternatives to currently used SVHC.  In the present work, we focused our attention on four 5 
plasticizers employed in food packaging: Di-iso-nonyl-phtalate (DiNP), Di-iso-decyl-phtalate 6 
(DiDP), Diethylen glycol dibenzoate (DEGDB), and Tri-m-cresyl phosphate (TMCP). 7 
Notably, DiNP and DiDP are comprised in the EFSA list of permitted compounds and are 8 
indeed among the most used in the plastic market (33% United States; 63% European 9 
Union) as substitutes of di(2-ethylhexyl) phthalate (DEHP), a substance classified as SVHC 10 
[9,10]. DEGDB is another emerging plasticizer designed to substitute phthalates, since it is 11 
considered more eco-friendly due to its biodegradation pathways [11]. Tri-cresyl 12 
phosphates, such as tri-m-cresyl phosphate (TMCP), are mainly used as substitutes of the 13 
plasticizers polybrominated diphenyl ethers (e.g. BDE-47) [12]. Along with the increased 14 
usage of these SVHC substitutes as alternative plasticizers, new biomonitoring data are 15 
becoming available associating the exposure to these chemicals with adverse effects in 16 
living beings. Notably, DiNP and DiDP have both been associated with increased insulin 17 
resistance in adolescent cohorts [13] and in general with several different adverse effects 18 
after peri- and post-natal exposure [14]. Interestingly, in silico approaches demonstrated 19 
that DiNP and DiDP can act as ligands of human peroxisome proliferator activated receptor 20 
γ (PPARγ) and retinoid-X-receptor-α (RXRα), possibly triggering a cascade of intracellular 21 
events [15]. DiDP is also a confirmed modulator of PPAR:RXR-dependent gene expression 22 
pathways in fish hepatocytes [16]. Similarly, TMCP was found to affect lipid/cholesterol 23 
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metabolism through a functional interplay between PPARs and liver X receptor (LXR) in a 1 
fish in vitro system [17]. Also, in fish DEGDB was demonstrated to have high affinities for 2 
PPARα, RXRα and LXR, showing the ability to modulate PPARα transcriptional pathways 3 
[18]. 4 
The 3T3-L1 preadipocyte cell line has proved to be a useful tool to study in vitro mechanisms 5 
by which obesogens can affect lipid accumulation and adipocyte differentiation. In 3T3-L1 6 
cells, these two processes are regulated by a strict transcriptional activity in which PPARγ 7 
is the master regulator [19]. During adipocyte differentiation, three different time windows 8 
can be distinguished, each one characterized by the upregulation/activation of a different 9 
set of transcription factors: an early phase of induction, characterized by the upregulation of 10 
Cebp (CCAAT/enhancer binding protein) β and δ and the activation of Cebpβ and Rxrs; a 11 
middle phase, with RXRα and PPARγ2 as obligate heterodimers; a late phase, where 12 
adipocyte specific genes such as Fabp4/Ap2 (Fatty Acid Binding Protein 4/Adipocyte Protein 13 
2), Lpl (Lipoprotein Lipase), AdipoQ (adiponectin) and leptin are upregulated [20–22]. 14 
Several studies have shown how environmental chemicals can perturb this intracellular 15 
cascade by targeting transcription factors and consequently enhance or decrease 16 
adipogenesis [5,6,22–24]. For example, certain EDCs may target PPARγ by binding to it 17 
directly to activate downstream cascades leading to enhanced lipid accumulation or by 18 
increasing PPARγ expression to favour its activation [24]. 19 
In the present work we used 3T3-L1 preadipocytes to investigate the possible adipogenic 20 
effects of plasticizers considered safe SVHC substitutes and used in FCMs manufacturing. 21 
First, we evaluated possible modifications in lipid accumulation following exposure to scalar 22 
concentrations of the plasticizers DiNP, DiDP, DEGDB and TMCP. Since adipogenesis 23 
7 
 
occurs in 3T3-L1 with a defined timeline of transcription factors and receptors activity, we 1 
also evaluated the possible different effects of plasticizer exposure alternatively during 3T3-2 
L1 early or mid-late differentiation. We then verified, by in silico molecular docking analysis 3 
and reporter gene assays, the ability of these molecules to bind and activate the major 4 
transcription factor involved in adipogenesis, namely PPARγ. To better understand the 5 
intracellular mechanisms underlying the changes in the adipogenic process, we investigated 6 
the regulation of the expression of genes belonging to the early, mid and late phase of 7 
adipocyte differentiation.  8 
 9 
 10 
2. Material and Methods 11 
2.1. Chemicals/Reagents 12 
All the reagents for cell culture (including medium supplements), Oil Red O (CAS Number 13 
1320-06-5), Rosiglitazone (BRL49653; CAS Number 122320-73-4, purity ≥98%), DiNP (di-14 
iso-nonyl-phtalate; CAS Number 28553-12-0, purity ≥99%), DiDP (di-iso-decyl-phtalate; 15 
CAS Number 26761-40-0, purity ≥99%), DEGDB (diethylene glycol dibenzoate; CAS 16 
Number  120-55-8, purity 90%), TMCP (tri-m-cresyl phosphate; CAS Number 563-04-2) and 17 
BPA (Bisphenol A; CAS Number 80-05-7, purity ≥99%) were obtained from Sigma Aldrich 18 
(USA). 19 
 20 
2.2. 3T3-L1 culture and adipocyte differentiation experiments 21 
3T3-L1 preadipocytes (ATCC® CL-173TM; ATCC, USA) were cultured in Dulbecco’s modified 22 
8 
 
Eagle’s medium high-glucose (DMEM) supplemented with 10% calf serum, 2 mM L-1 
glutamine, 50 IU/mL penicillin, and 50 μg/mL streptomycin. 2x104 cells/well were seeded in 2 
24-well plates. Two days after reaching confluence (day 0), cells were exposed to the 3 
differentiation medium (MDI; DMEM containing 10% fetal bovine serum, 1 μg/mL insulin, 1 4 
μM dexamethasone, 0.5 mM isobutylmethylxanthine). Two days later (day 2), MDI medium 5 
was replaced with maintenance medium (MM; DMEM 10% FBS, 1 μg/mL insulin). Fresh 6 
medium was provided every two days. Experiments were ended after 10 days from the 7 
beginning of the differentiation (day 10). 8 
Cells were exposed to the following plasticizers: DiNP, DiDP, DEGDB, TMCP or BPA at 9 
concentrations ranging from 0.01 to 25 µM, that were excluded to be toxic by visual analysis. 10 
100 nM Rosiglitazone was used as a positive control. All the chemicals were dissolved in 11 
100% DMSO as vehicle, and cells were exposed to a final concentration of 0.1% DMSO. 12 
Cells were treated with chemicals alternatively from day 0 to day 10 (whole differentiation 13 
period treatment), from day 0 to day 2 (early phase treatment), or from day 2 to day 10 14 
(middle-late phase treatment). Control cells were kept in MDI plus 0.1% DMSO from day 0 15 
to day 2 and in MM plus 0.1% DMSO from day 2 to day 10.  16 
Three independent replicates were set in each experiment; experiments were repeated 17 
three times at different passage numbers (p8-p11). 18 
 19 
2.3. Quantification of adipocyte lipid accumulation 20 
Lipid accumulation in 3T3-L1 adipocytes was determined by quantitative Oil Red O (ORO) 21 
staining at day 10. Oil Red O was dissolved in isopropanol overnight at a concentration of 22 
0.35%, followed by 0.2 µm filtration, dilution in water to a final concentration of 0.2%, and 23 
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refiltration. Adipocytes were washed twice with PBS, then they were fixed in 10% 1 
paraformaldehyde for 10 min at room temperature. Cells were washed with ddH2O, allowed 2 
to dry, and stained with ORO solution for 20 min. Following several washes with ddH2O, 3 
plates were dried at room temperature; ORO was then eluted in 100% isopropanol, and 4 
absorbance at 500 nm was measured using a microplate reader (BioRad, USA). The mean 5 
of 8 absorbance readings (technical replicates) was calculated for each sample; three 6 
independent plate replicates were set in each experiment and experiments were repeated 7 
three times. Variations in lipid accumulation were expressed as fold changes of the 8 
absorbance of treated cells relative to the absorbance of control cells; controls were 9 
assigned a value of 1. 10 
Results are expressed as the mean of the values obtained in the three independent 11 
experiments ± standard error of the mean (SEM). 12 
 13 
2.4. Molecular docking studies 14 
Molecular docking analysis were performed using Autodock Vina 1.1.2 [25] on an Intel Core 15 
i7/Mac OS X 10.9 – based platform, setting a docking zone of 24, 26, and 28 points (in the 16 
x, y, and z directions) and of 26, 25, and 27 points with a grid spacing of 1 Å over the human 17 
PPARγ and RXRα binding site, respectively.  18 
The crystallographic structures of PPARγ and RXRα receptors were obtained from the 19 
Protein Data Bank [26]: PPARγ 1I7I.pdb [27], RXRα 3DZY.pdb [28]. The molecular 20 
structures of ligands were obtained from the PubChem database [29] and minimized (with 21 
a universal force field, UFF, and a conjugate gradient algorithm until a ΔE lower than 22 
0.001kJ/mol) using the Avogadro software (Version 1.1.0; 23 
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http://avogadro.openmolecules.net/) [30].  1 
The affinity constants, expressed as equilibrium dissociation constants (Kd), were 2 
determined analysing the 10 best complexes, obtained for each ligand from Autodock Vina, 3 
with the NNScore algorithm, version 2.0 [31].  4 
All models and images were rendered using UCSF Chimera software, version 1.11 [32], 5 
whereas 2D ligand interaction diagrams were obtained using Maestro software, version 10.6 6 
(Schrödinger, LLC, USA). 7 
 8 
2.5. Transfection and reporter gene assays 9 
HepG2 human hepatoblastoma cell line (ATCC® HB-8065TM; ATCC, USA) was used for 10 
gene reporter assays; cells were plated on a 24 well plate and then transfected with the 11 
following constructs [33,34]: (1) 1.5 µg DR1-Luc (containing a direct repeat 1 upstream of 12 
luciferase gene), (2) 100 ng pCMV-βgal (pCMV-β-galactosidase normalization plasmid), and 13 
(3) 400 ng pcDNA3-PPARγ (an expression vector for human PPARγ) using Lipofectin 14 
(Invitrogen). As described previously [35], cells were treated with the indicated ligands 24 15 
hrs post transfection and assayed for luciferase activity 24 hrs post-treatment. Luciferase 16 
activity was normalized to β-galactosidase activity to control for transfection efficiency. 17 
 18 
2.6. Gene expression analysis 19 
Cells were exposed from day 0 to 25 µM DiDP, DEGDB, TMCP or 100 nM Rosiglitazone; 20 
control cells were treated with 0.1% DMSO. Three independent replicates were set in each 21 
experiment; experiments were repeated three times. Total RNA was isolated from control 22 
and treated 3T3-L1 cells at day 2, day 4 and day 8. Briefly, cells were washed with PBS and 23 
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Tri-Reagent (Sigma, USA) was used for RNA extraction following manufacturer guidelines. 1 
qReal-Time PCR was performed using Superscript III Platinum One-step qRT-PCR system 2 
(Invitrogen, USA) and the thermal cycler Rotor Gene Q (Qiagen, Germany). Intron-spanning 3 
primers for representative genes were designed with Primer-BLAST software (NCBI, USA) 4 
and are listed in Table 1. Each sample was analysed in three technical replicates containing 5 
50 ng of total RNA. The relative quantification of gene expression was done using a standard 6 
curve that was built by pooling all the RNA samples and making serial dilutions (range: 200-7 
6.25 ng of total RNA). The amplicon concentrations were expressed in arbitrary units and 8 
were normalized for the expression of β-actin, a commonly used housekeeping gene, proved 9 
to be a suitable reference gene for qRT-PCR expression studies in 3T3-L1 cells [36]. For 10 
each gene, the mRNA expression of the samples was reported as fold changes relative to 11 
the expression of control cells; controls were assigned a value of 1. 12 
 13 
2.7. Statistical analysis 14 
Statistical analysis was performed with SPSS software (version 24; IBM, USA). All data were 15 
analysed with one-way ANOVA plus Tukey or Bonferroni post-hoc test (p<0.05). Data were 16 
expressed as fold changes versus control ± standard error of the mean (SEM) or ± standard 17 
deviation (SD); controls were assigned a value of 1. 18 
 19 
 20 
3. Results 21 
3.1. The plasticizers DiNP, DiDP, DEGDB and TMCP enhance lipid accumulation in 22 
3T3-L1 cells 23 
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We evaluated the effect of four plasticizers belonging to different chemical categories (the 1 
phthalates DiNP and DiDP, the benzoate ester DEGDB and the organophosphate TMCP) 2 
on adipocyte differentiation by assessing lipid accumulation using Oil Red O (ORO) staining. 3 
The plasticizer BPA (Bisphenol A), whose well-documented pro-adipogenic effects have 4 
been ascribed to multiple pathways [37], was included as a reference compound; another 5 
reference molecule included in the study was Rosiglitazone (BRL49653), because of its well-6 
defined agonist activity toward PPARγ [24]. 3T3-L1 preadipocytes were induced to start 7 
adipogenic differentiation and were treated throughout differentiation with vehicle only (0.1% 8 
DMSO) or with scalar concentrations (0.01-25 μM) of each plasticizer, while Rosiglitazone 9 
was used at a concentration of 100 nM, selected according to published data [6,24,38]. At 10 
the end of the experiment (day 10), lipid accumulation was measured by ORO lipid staining 11 
and quantification (Fig. 1). As expected, 100 nM Rosiglitazone-exposed cells displayed a 12 
strong enhancement (about 7 folds) in lipid accumulation in respect to untreated cells 13 
(cultured in MDI-MM medium containing 0.1% DMSO). BPA exerted a clear dose-dependent 14 
enhancement of lipid accumulation, the highest concentration (25 µM) being markedly more 15 
effective in inducing lipidogenesis than lower concentrations (5 folds for 25 µM versus 1.2-16 
1.8 folds for 0.01-10 µM). Interestingly, also DiNP, DiDP, DEGDB, and TMCP led to a 17 
significant increase in lipid accumulation at all tested concentrations.  Although lower than 18 
the maximal effect reached by the highest doses of BPA, the increase induced by 19 
plasticizers was about 20-50% compared to control cells, with TMCP being the most 20 
effective plasticizer at all concentrations.  21 
 22 
3.2. Plasticizers are more effective in enhancing lipid accumulation when 23 
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administered during mid-late differentiation 1 
Since lipidogenesis occurs in 3T3-L1 cells with a defined timeline of transcription factors and 2 
receptors activity, we tried to identify windows of susceptibility to plasticizer exposure. For 3 
this purpose, plasticizers were added at the lowest concentration tested (0.01 µM) 4 
alternatively during the early (day 0-2) or the mid-late differentiation (day 2-10) and lipid 5 
accumulation was measured by ORO staining at day 10. An increase in lipid accumulation 6 
was observed both when 3T3-L1 cells were treated with plasticizers during the early or the 7 
mid-late differentiation (Fig. 2). However, the highest effect on lipidogenesis was reached 8 
when plasticizer administration was performed during the mid-late differentiation, except for 9 
BPA, for which no statistically significant differences were seen between the two phases. 10 
Notably, when administered at 0.01 µM during the mid-late differentiation, BPA resulted the 11 
least effective molecule in inducing lipidogenesis, while TMCP was the most effective one.  12 
As a matter of fact, exposure to TMCP at days 2-10 was 37% more effective than exposure 13 
at days 0-2 (2.33 versus 1.70 folds relative to control), indicating that the mid-late 14 
differentiation is considerably more sensitive to TMCP. 15 
 16 
3.3. Computational analysis predicts specific interactions of the plasticizers with 17 
PPARγ and RXRα 18 
Metabolic disruptors are known to control lipidogenesis and adipocyte differentiation 19 
interacting with transcription regulators of gene networks, the main of which belong to the 20 
PPAR and RXR receptor families. Since our above-reported results show that plasticizers 21 
can enhance in vitro 3T3-L1 preadipocytes lipid accumulation, we evaluated if these 22 
plasticizers could potentially act via an interaction with the nuclear receptors PPARγ and 23 
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RXRα. In silico molecular docking analysis, that consider the affinity and the geometry of 1 
binding, actually showed the capability of DiNP, DiDP and TMCP to specifically bind the 2 
PPARγ receptor with affinities ranging in the submicromolar order; as expected, BPA 3 
showed a lower affinity for PPARγ, in respect to the other plasticizers. All the ligands 4 
analysed showed a higher binding affinity with RXRα, although their predicted equilibrium 5 
dissociation constants for PPARγ are in the same order of magnitude (Table 2). To validate 6 
the molecular docking procedure, we added Rosiglitazone to the ligands set and found a 7 
predicted equilibrium dissociation constant for PPARγ highly comparable to the Kd value 8 
already published [39]. Moreover, the molecular docking model of the best predicted 9 
Rosiglitazone/PPARγ complex and the crystallographic structure of this complex 10 
(4EMA.pdb) [40] are extremely comparable (data not shown), on the basis of both 11 
orientation and average distance of each atom of the ligand (RMSD value = 1.05Å). Among 12 
the molecules analysed, TMCP resulted to be the best ligand for PPARγ and RXRα 13 
receptors, showing two equilibrium dissociation constants comparable to those of 14 
Rosiglitazone. Molecular docking analysis between TMCP and the two receptors ligand 15 
binding domains showed that TMCP is exclusively stabilized by non-polar interactions and, 16 
in particular, it could establish a pi-pi stacking interaction with Arg288 of PPARγ and with 17 
Phe313 of RXRα (Fig. 3).   18 
 19 
 3.4. Plasticizers can transactivate PPARγ 20 
We confirmed the ability of the plasticizers TMCP, DiDP, DiNP and DEGDB to bind and 21 
activate PPARγ by examining their capacity to induce PPARγ-driven reporter expression 22 
following transient transfection of HepG2 cells with pcDNA3-PPARγ.  In this assay, all 23 
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plasticizers significantly induced PPARγ-driven reporter activity at a concentration of 25 μM, 1 
with DiNP and TMPC being already active at 10 µM (Fig. 4). The maximal activity was 2 
reached by 25 µM TMCP, that lead to an induction of 2.5 folds, corresponding to about half 3 
of the induction obtained by 10 µM Rosiglitazone. 4 
 5 
3.5. Plasticizers modulate the expression of adipogenic marker genes 6 
Differentiation of 3T3-L1 preadipocytes, similarly to what occurs in vivo, involves a 7 
transcriptional cascade initially activated by an adipogenic cocktail (MDI, see Methods) 8 
inducing, among others, the transcription factor Cebpβ (early phase of differentiation). 9 
CEPBβ is a direct activator of Pparγ transcription (mid phase), and  7-12)PPARγ in turn 10 
binds as an obligate heterodimer with the nuclear receptor RXR to numerous promoter sites 11 
of adipocyte specific genes (late phase), including Fabp4/Ap2 and Lpl. In the effort to further 12 
elucidate the mechanisms of plasticizer action on preadipocyte differentiation, we analysed 13 
by qReal-Time PCR the expression of Cebpβ, Rxrα, Pparγ2, Fabp4/Ap2 and Lpl transcripts 14 
at day 2, day 4 or day 8 post-induction. 3T3-L1 cells were exposed to 100 nM Rosiglitazone 15 
or to 25 μM TMCP, DiDP and DEGDB, a concentration able to induce the highest lipid 16 
accumulation in the absence of cytotoxic effects.  17 
At day 2 (Fig. 5, upper panel), corresponding to the early phase of adipogenic differentiation, 18 
all the tested molecules were able to enhance the expression of the Cebpβ transcript, 19 
suggesting that Rosiglitazone, TMCP, DiDP and DEGDB can influence the first steps of 20 
differentiation by regulating the expression of this early gene. On the other hand, at day 4 21 
(Fig. 5, lower panel) only DEGDB still enhanced Cebpβ mRNA expression. The expression 22 
of Rxrα was selectively modified only by Rosiglitazone administration both during the early 23 
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(day 2; Fig. 5, upper panel) and mid phase of differentiation (day 4; Fig. 5, lower panel). The 1 
expression of Pparγ2, the adipogenesis master gene, was markedly increased at day 2 (Fig. 2 
5, upper panel) by DiDP and DEGDB, while Rosiglitazone and TMCP did not exert any 3 
effect. At day 4 (Fig. 5, lower panel) all the analysed plasticizers were able to increase 4 
Pparγ2 mRNA expression. Overall, the plasticizer-induced regulation of Pparγ2 expression 5 
on day 2 and 4 was quite similar to the one exerted by Rosiglitazone. 6 
As expected, in the late phase of differentiation (day 8) (Fig. 6), the levels of the Fabp4 7 
transcript were highly increased by Rosiglitazone. The plasticizers TMCP and DEGDB had 8 
also a positive effect (4 and 3.5 folds respectively compared to untreated cells) on the 9 
expression of this transcript. Lpl, another adipogenesis marker gene belonging to the late 10 
phase, was modulated by Rosiglitazone and TMCP at comparable levels (about 8 and 6 11 
folds respectively). Conversely, the expression of both Fabp4 and Lpl was not modified by 12 
exposure to the phthalate DiDP. 13 
 14 
4. Discussion 15 
Plasticizers and their metabolites are a frequent finding in human biomonitoring data of 16 
industrialized countries [41–46]. Published datasets in national surveys referring to the last 17 
decade track the coexistence of both dismissed compounds, still present in relevant 18 
amounts, and new plasticizers and their metabolites [45,46]  that are slowly substituting the 19 
former ones. Some of the new plasticizers could represent an emerging class of 20 
contaminants, therefore evaluation of their potential biological effects is needed [47]. 21 
The results of the present study suggest that plasticizers considered safer alternatives to 22 
SVHC may actually affect metabolic processes, such as adipogenesis.  We demonstrate 23 
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that low nanomolar concentrations of four plasticizers currently used in FCMs manufacturing 1 
(namely DiNP, DiDP, DEGDB and TMCP) enhance the ability of 3T3-L1 cells to differentiate 2 
into mature adipocytes, as shown by a 1.2-2.3 fold increase in lipid accumulation, depending 3 
on the chemical and time window of exposure.  Computational analysis shows the capability 4 
of these compounds to bind to PPARγ and RXRα, two nuclear receptors specifically involved 5 
in the adipogenic transcriptional cascade. Each plasticizer was able to transactivate PPARγ 6 
and to modulate the expression of adipogenic marker genes to various extents.  By 7 
analysing the regulation of Pparγ2 gene expression exerted by test plasticizers we found a 8 
certain similarity to the one exerted by Rosiglitazone, a PPARγ agonist, suggesting some 9 
degree of overlapping in the cellular mechanisms involved. 10 
Besides Rosiglitazone, we included also BPA as a useful reference compound in all our 11 
experiments, since considerable amount of knowledge has been accumulated from in vitro 12 
and in vivo studies on this plasticizer. While some controversy exists in epidemiological data 13 
associating BPA exposure and development of obesity and/or metabolic syndrome in human 14 
populations [2,3,48] , several animal studies demonstrate that exposure to BPA can affect 15 
adipogenesis [2,3,37].  In addition, a number of studies on 3T3-L1 cells have shown that 16 
BPA administered during adipocyte differentiation increases lipid accumulation, generally 17 
from 2 to 5 folds compared to control, depending on protocol and dosage [24,49–53]. Our 18 
results regarding BPA are in line with most previous literature data. 19 
Phthalate pro-obesogenic effects in the human population are still under investigation. Some 20 
studies relate the presence of phthalates in blood samples and urine with an increased risk 21 
of obesity and metabolic syndrome [54–57], however in a context of a larger dataset these 22 
links seem to have some uncertainty [58]. Differently from epidemiological data, there is 23 
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extensive knowledge that phthalates exposure, particularly DEHP and its metabolite mono 1 
(2-ethylhexyl) phthalate (MEHP), have negative outcomes on glucose and lipid homeostasis 2 
in cellular and animal models [47,58,59]. However, there are scarce or no studies on the 3 
emerging phthalate substitutes DiNP and DiDP. We show that low nanomolar 4 
concentrations of DiNP and DiDP are able to enhance lipid accumulation from 20% to 80%, 5 
depending on the time-frame of administration. While this is the first report showing  that 6 
DiDP can increase lipidogenesis in 3T3-L1 adipocytes, a previous study reported small 7 
statistically significant effects of DiNP on lipid accumulation [24]. Human biomonitoring 8 
studies employing metabolites of DiNP and DiDP as biomarkers of exposure, reported 9 
median values of 5.10 g/L (16 nM) for MCiOP (mono carboxy-isooctyl phthalate, a DiNP 10 
metabolite) and 2.7 g/L (7.9 nM) for MCiNP (mono-carboxy-isononyl phthalate, a DiDP 11 
metabolite) in the urine of the United States general population (>6 years, 2005-2006 survey, 12 
Calafat et al. [60]).  These levels found in urine are comparable to the 10 nM concentration 13 
used in our experiments. Additional studies compared the levels of phthalate metabolites in 14 
urine among mother-child pairs [61,62] showing that children’s DiNP and DiDP metabolite 15 
excretion was higher than that of the mothers, indicating a possible higher children 16 
exposure. In addition, multiple studies [62,63] found a significant temporal decline over the 17 
last 15-20 years in urinary levels of metabolites of strictly regulated phthalates (such as 18 
DHEP), paralleled by a marked increase in urinary metabolite concentrations of DiNP and 19 
DiDP. Given the existing biomonitoring data and the results of our study, further research 20 
on the adverse health effects of DiNP and DiDP, including obesity and metabolic 21 
dysfunctions, is warranted. 22 
19 
 
DEGDB is defined by many as a “green plasticizer”. There are currently no published human 1 
biomonitoring studies on this chemical and there is only some preliminary evidence of the 2 
potential impact of DEGDB on tissue-specific regulation of genes involved in lipid 3 
metabolism and energy balance in vivo [18]. In our in vitro experiments, DEGDB actually 4 
showed a lipidogenic effect similar to that of the phthalates DiNP and DiDP. To the best of 5 
our knowledge, this is the first report linking this compound to in vitro-induced adipogenesis. 6 
TMCP belongs to the class of organophosphates, a group of compounds that range from 7 
slightly to highly toxic depending on chemical structure, dose and route of exposure [64,65]. 8 
Epidemiological data on organophosphates indicate that a prenatal exposure may lead to 9 
adverse effects on glucose metabolism at birth [66], but little is known about the outcomes 10 
of long-term exposure and adult datasets often report controversial results [67]. Concerning 11 
animal studies, recent data show that a chronic or subchronic dietary or perinatal exposure 12 
to organophosphates alters metabolic functions causing an obese-like phenotype and a 13 
diabetic profile in mice [68–70] and rat models [71,72]. Although there are no data available 14 
on TMCP effects in 3T3-L1 adipocytes, recent results on the organophosphate triphenyl 15 
phosphate (TPhP) indicate that this molecule is able to increase 3T3-L1 preadipocyte 16 
proliferation and subsequent adipocyte differentiation, as well as glucose uptake and 17 
lipolysis [73].  TMCP was the most effective compound in enhancing lipid accumulation 18 
among the plasticizers we tested. This evidence, together with the fact that this 19 
organophosphate showed the highest computational binding affinity and capability to 20 
transactivate PPARγ, potentially make TMCP the most obesogenic of the four plasticizers 21 
that we tested.  Clearly, in vivo studies are needed to confirm the plasticizer obesogenic 22 
potentials defined in vitro in the present study.  23 
20 
 
To elucidate the mechanism by which DiNP, DiDP, DEGDB and TMCP enhance lipid 1 
accumulation in 3T3-L1 cells, we evaluated by computational analysis their interaction with 2 
PPARγ and RXRα. In silico binding affinity of plasticizers for PPARγ and RXRα receptors 3 
was highly indicative of in vivo interactions, particularly for TMCP whose Kd values were 4 
similar to those calculated for Rosiglitazone. BPA showed a higher Kd value for PPARγ, 5 
suggesting an action mainly through other nuclear receptors. The predicted interaction of 6 
the plasticizers with PPARγ was confirmed by transient transfection studies and is in line 7 
with the significant increase found in the expression of the PPARγ target gene Fabp4 after 8 
exposure to plasticizers during differentiation. These data are in agreement with previous 9 
studies suggesting that phthalates and TMCP or TPhP can modulate the regulatory 10 
mechanism of lipid metabolism pathways through PPARs and RXRs [15–17,74]. Another 11 
significant result from our data is that both DiNP and TMCP show high binding affinity for 12 
RXRα. This finding, which is a common trend for other potential obesogens [16,59,75], 13 
suggests that binding of these plasticizers to RXRα may independently increase PPARγ 14 
transcriptional activity. This possibility, although needing experimental confirmation, is in line 15 
with the “permissive” features of the PPARγ/RXRα heterodimer [76], meaning that also RXR 16 
ligands can activate it, amplifying the effects on downstream genes. Taken together, in silico 17 
predictions and transactivation experiments suggest that the mechanisms through which 18 
DiNP, DiDP, DEGDB and TMCP increase lipid accumulation involve the direct activation of 19 
the PPARγ/RXRα complex. 20 
It is expected that the effect of plasticizers on lipid accumulation in 3T3-L1 cells is linked to 21 
and, perhaps, promoted by modifications in the pro-adipogenic transcription factor cascade. 22 
In order to test this hypothesis, we analysed a set of transcripts that play a key role in the 23 
21 
 
adipogenic process: Cebpβ, Rxrα, Pparγ2, Fabp4 and Lpl. In the early phase of adipocyte 1 
differentiation, all plasticizers were able to increase Cebpβ expression, a transcription factor 2 
playing a crucial role in the induction of 3T3-L1 differentiation and required for the binding 3 
to genomic adipogenic hotspots of other adipogenic transcription factors [19,77]. CEPBβ is 4 
a direct activator of Pparγ transcription, therefore an increase in Cebpβ expression is 5 
expected to reverberate on Pparγ expression [77,78]. In line with this, we found that all 6 
plasticizers induced also a significant enhancement in Pparγ2 transcript levels in the middle-7 
late phase of differentiation. Exposure to plasticizers only in the early phase (days 0-2), 8 
corresponding to the enhancement of Cebpβ expression, was enough to induce a significant 9 
increase in lipid accumulation measured at the end of differentiation (day 10).  This result 10 
suggests that any molecule able to modify the expression and therefore the activity of 11 
CEPBβ can have profound consequences on adipocyte differentiation.  We can hypothesize 12 
that the plasticizers could increase the expression of Cebpβ through the activation of the 13 
cAMP response element–binding protein (CREB) and the glucocorticoid receptor (GR), 14 
however recently additional transcription factors have been found to regulate Cebpβ 15 
transcription as a consequence of different adipogenic stimuli [21,79]. We observed no 16 
changes in the expression of the Rxrα gene, except for a moderate increase exerted by 17 
Rosiglitazone. Absence of regulation of Rxrα expression was somehow expected, since 18 
previous studies showed that the human Rxrα gene displays features of a housekeeping 19 
gene [80]. Additional studies report that RXRα activity is modulated by extensive 20 
posttranslational modifications and proteasomal degradation [76], suggesting that RXRα is 21 
mainly regulated at the protein level. Like Rosiglitazone, in the late phase of 3T3-L1 cell 22 
differentiation TMCP was able to modulate the expression of the adipogenesis marker genes 23 
22 
 
Lpl and Fabp4. Similarly to our result, a recent study [73] reported that 25 µM of the 1 
organophosphate TPhP is able to increase 3T3-L1 differentiation by upregulating the 2 
expression of Cebpβ, Pparγ and Lpl during early and mid-late differentiation, respectively. 3 
Activation of PPARand increased differentiation of 3T3-L1 cells into adipocytes by 4 
phthalates (i.e. MHEP and DHEP) has been previously reported [81–83]. Nonetheless, this 5 
effects not always correlated with a modulation in late genes involved in lipidogenesis [84]. 6 
Similarly, we also observed that DiDP and DEGDB were both unable to modify Lpl transcript 7 
levels. It is possible that other late genes, not considered in our study, are regulated by these 8 
plasticizers. In addition, both DiDP and DEGDB were able to activate PPARγ in transient 9 
transfection studies only at the highest concentration (25 μM), therefore showing a lower 10 
capability to interact with PPARγ compared to TMCP. 11 
The plasticizer-mediated enhancement of lipid accumulation in 3T3-L1 cells was present 12 
when exposing cells both in the early or in the mid-late phase of adipogenic differentiation. 13 
However, plasticizers were more effective when added during mid-late differentiation. We 14 
can postulate that when plasticizers are delivered in the early phase, they positively 15 
modulate Cebpβ transcription, leading to enhanced PPARγ expression and receptor 16 
availability in the subsequent steps of the lipidogenic process. On the other hand, if 17 
plasticizers are added in the mid-late phase, when PPARγ is highly expressed, they can 18 
interact directly with this receptor. As a result, lipid accumulation increases even further 19 
compared to the early phase treatment. We observed that cells exposed to BPA did not 20 
behave differently in the two phases, possibly because of the low BPA binding affinity for 21 
PPARγ.  Multiple intracellular pathways involved in the induction of adipogenesis by BPA 22 
have been described [85,86], mostly characterized by PPARγ/RXRα independent 23 
23 
 
mechanisms [37,86,87]. The wide range of 3T3-L1 cells responses observed after plasticizer 1 
treatments probably reflects not only the multiple pathways engaged by each type of 2 
chemical compound [88], but also the high complexity of the cell processes leading to the 3 
differentiation into mature adipocytes [20,89].  4 
 5 
5. Conclusions 6 
Our study demonstrates that the plasticizers DiNP, DiDP, DEGDB and TMCP, used as safer 7 
alternatives to SVHC chemicals, are able to interfere with the adipogenic process in 3T3-L1 8 
cells at low nanomolar concentrations. Our results suggest that the observed increase in 9 
lipid accumulation is at least partly mediated by direct binding to the transcription factors 10 
PPARγ and RXRα and through regulation of several genes involved in the adipogenic 11 
transcriptional cascade. The effect of single chemicals on lipid accumulation was moderate, 12 
however it should be considered that multiple plasticizers often occur in the same FCM, 13 
therefore the global effect of singularly active plasticizers could be significantly higher in 14 
mixtures. For this reason, future studies should address the metabolic effects of mixtures 15 
containing TMCP, DiNP, DiDP and DEGDB.  Our findings also suggest that these four 16 
plasticizers may not be harmless substitute of currently restricted compounds.  Given the 17 
growing exposure of humans to these plasticizers, further in vivo investigation of their effects 18 
is warranted.  19 
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Figure and Table captions 4 
Fig. 1. Scalar concentrations of BPA, DiNP, DiDP, DEGDB and TMCP enhance lipid 5 
accumulation in differentiated 3T3-L1 cells. 6 
Upper left panel: schematic representation of the experimental protocol (for details, see 7 
Materials and Methods section). The blue line indicates the presence of plasticizers (or 8 
Rosiglitazone) in the cell culture medium. MDI: differentiation medium; MM: maintenance 9 
medium. Graphs show quantification of lipid accumulation by Oil Red O (ORO) staining, 10 
elution and absorbance reading. Three independent experiments (n=3) with 3 biological 11 
replicates each were carried out. Variations in lipid accumulation were expressed as fold 12 
changes of the absorbance of treated cells relative to the absorbance of control cells (=1) ± 13 
SEM; *** p<0.001. 14 
 15 
Fig. 2. Low nanomolar concentrations of plasticizers are more effective in enhancing 16 
lipid accumulation when administered during mid-late differentiation. 17 
Upper left panel: schematic representation of the experimental protocol (for details, see 18 
Materials and Methods section). The blue lines indicate the presence of plasticizers (0.01 19 
µM) in the cell culture medium. MDI: differentiation medium; MM: maintenance medium. 20 
Graphs show quantification of lipid accumulation by Oil Red O (ORO) staining, elution and 21 
absorbance reading. 3T3-L1 preadipocytes were treated with plasticizers alternatively from 22 
day 0 to day 2 (early differentiation) or from day 2 to day 10 (mid-late differentiation). Three 23 
40 
 
independent experiments (n=3) were carried out with 3 biological replicates each. Variations 1 
in lipid accumulation were expressed as fold changes of the absorbance of treated cells 2 
relative to the absorbance of control cells (=1) ± SEM. * differences versus control; # 3 
differences between early and mid-late differentiation; * p<0.05; ** p<0.01; *** p<0.001; ## 4 
p<0.01; ### p<0.001. 5 
 6 
Fig. 3. TMCP is predicted to interact with both PPARγ and RXRα ligand binding 7 
domains. 8 
3D (left side) and 2D (right side) predicted models of the TMCP/PPAR (A) and TMCP/RXR 9 
(B) complexes obtained by molecular docking. In the 3D representations, the receptor is 10 
shown in cartoon mode, whereas TMCP is shown as stick. Predicted non-polar interactions 11 
between TMCP and PPARγ Arg288 / RXRα Phe313 are reported in the 2D schemes. See the 12 
Material & Methods section for methodological details.   13 
 14 
Fig. 4. Plasticizers can transactivate PPARγ. 15 
HepG2 cells were transfected with pcDNA3-PPARγ, DR1-Luc, and pCMV-β-galactosidase 16 
vectors, then were treated with scalar concentrations of Rosiglitazone or plasticizers as 17 
described under Material & Methods. Luciferase activities are reported as fold changes of 18 
luminescence of treated cells versus control (=1) ± SEM (n=3). * p<0.05. 19 
 20 
Fig. 5. All plasticizers modulate the expression of Cebpβ and Pparγ2 in the early 21 
and/or mid phase of 3T3-L1 pre-adipocyte differentiation. 22 
Left panels: schematic representations of the experimental protocol. The blue line indicates 23 
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the presence of plasticizers (25 µM) or Rosiglitazone (100 nM) in the cell culture medium. 1 
MDI: differentiation medium; MM: maintenance medium. mRNA expression was evaluated 2 
by qReal-Time PCR at day 2 (upper panel) or at day 4 (lower panel). Data are expressed 3 
as fold changes in mRNA expression versus control (=1) ± SD. * p<0.05; ** p<0.01; *** 4 
p<0.001. Graphs are representative of three independent experiments. 5 
 6 
Fig. 6. Among plasticizers, TMCP shows the highest similarity to Rosiglitazone in 7 
modulating the expression of late differentiation genes. 8 
Upper left panel: schematic representation of the experimental protocol. The blue line 9 
indicates the presence of plasticizers (25 µM) or Rosiglitazone (100 nM) in the cell culture 10 
medium. MDI: differentiation medium; MM: maintenance medium. mRNA expression was 11 
evaluated by qReal-Time PCR at day 8. Data are expressed as fold changes in mRNA 12 
expression versus control (=1) ± SD. * p<0.05; ** p<0.01; *** p<0.001. Graphs are 13 
representative of three independent experiments. 14 
 15 
Table 1. Primer sequences used for gene expression analysis 16 
 17 
Table 2. Predicted equilibrium dissociation constants (Kd,pred) between PPARγ, RXRα 18 
and a set of plasticizers 19 
  20 
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Table 1 1 
Primers Sequences 
Cebpβ Forward  5’ – CCTGAGTAATCACTTAAAGATGT – 3’ 
 Reverse  5’ – TTTAATGCTCGAAACGGAAA – 3’ 
Rxrα Forward  5’ – CGGAACAGCGCTCACAGT – 3’ 
 Reverse  5’ – AGCTCCGTCTTGTCCATCTG – 3’ 
Pparγ2 Forward  5’ – CTGTTATGGGTGAAACTCTG – 3’ 
 Reverse  5’ – ATGGCATCTCTGTGTCAA – 3’ 
Fabp4 Forward  5’ – GAATTCGATGAAATCACCGCA – 3’ 
 Reverse  5’ – CTCTTTATTGTGGTCGACTTTCCA – 3’ 
Lpl Forward  5’ – GATCCGAGTGAAAGCCGGAG – 3’ 
 Reverse  5’ – TTGTTTGTCCAGTGTCAGCCA – 3’ 
β-actin Forward  5’ – TCTTTGCAGCTCCTTCGTTG – 3’ 
 Reverse  5’ – ACGATGGAGGGGAATACAGC – 3’ 
 2 
 3 
Table 2 4 
 5 
 6 
 Kd,pred (M) vs PPARγ Kd,pred (M) vs RXRα 
BPA, Bisphenol A 1.40 ± 0.34 × 10-6 8.02 ± 1.38 × 10-7 
DiNP, Di-isononyl-phthalate 1.34 ± 0.24 × 10-7 6.09 ± 0.98 × 10-8 
DiDP, Di-isodecyl-phthalate 1.39 ± 0.31 × 10-7 1.72 ± 0.40 × 10-7 
DEGDB, Diethylene glycol dibenzoate  5.55 ± 1.24 × 10-7 3.74 ± 0.79 × 10-7 
TMCP, Tri-m-cresyl phosphate 4.27 ± 1.26 × 10-8 2.56 ± 0.40 × 10-8 
Rosiglitazone, BRL49653 4.92 ± 1.43 × 10-8 3.84 ± 0.72 × 10-8 
  7 
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Fig. 6 1 
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